Angioedema due to acquired deficiency of the C1-inhibitor is a bridging condition between autoimmunity and lymphoproliferation. We report 32 patients with acquired C1 inhibitor deficiency: 23 have anti C1-inhibitor autoantibodies; 13 have monoclonal gammopathies of unknown significance and 9 have non-Hodgkin's lymphoma. Our series suggest that different forms of B cell disorders coexist and/or evolve into each other in acquired angioedema. Haematologica 2007; 92:5: 716-718 Angioedema due to the acquired deficiency of the inhibitor of the first component of human complement (CI-INH) is a rare syndrome usually identified as acquired angioedema (AAE). One hundred and thirtysix cases are described literature.
This study aimed to clarify the relationship between the different forms of B cell proliferation present in AAE. Thirty-two patients were included, 23 of whom had been described elsewhere.
3 4 Thirteen of 32 AAE patients (40%) fulfilled the diagnostic criteria for MGUS. According to a previous report 5 MGUS and autoantibodies to C1-INH shared the same heavy and light chain isotypes in 9 patients.
Nine patients (28%) presented NHL. Based on WHO classification, 7 patients had indolent lymphoma (3 lymphoplasmacytoid lymphoma/Waldeström disease, 1 small lymphocytic lymphoma, 1 splenic marginal zone lymphoma, 1 nodal marginal zone B cells lymphoma) and 2 had high-grade malignant lymphoma (1 large B cell lymphoma and 1 mantle cell lymphoma with progression to large B cell lymphoma). All patients with indolent lymphoma had advanced stage with bone marrow infiltration. Follicular lymphoma, the most frequent istotype of indolent lymphoma, was only found in one patient. This agrees with other series of patients in which indolent lymphoma were described in the setting of autoimmune disorders.
6-7
In 7 out of 9 patients, NHL was diagnosed at the onset of angioedema or developed thereafter after a minimum of 3 months to a maximum of 7 years. In 2 patients NHL was already present, but not treated, when angioedema appeared, after 6 years and 3 months respectively.
Three patients received standard chemotherapy (CEOP: cyclophosphamide-vincristine and prednisone). One also received Rituximab and another received CEOP and subsequently fludarabine and cyclofosphamide for abdominal relapse. This last patient is still in complete remission after 6 years of follow up, while the other two died from lymphoma progression. One patient, with splenic marginal zone lymphoma, received splenectomy and no chemotherapy, and is in remission after 4 years of follow up. In the remaining 5 patients the disease is stable without therapy. Levi et al. 8 recently reported the remission of C1-INH induced acquired angioedema following Rituximab treatment. In our study, the three patients who received chemotherapy remained asymptomatic after treatment.
Monitoring of complement parameters in two of them showed reversal of the biochemical abnormalities (Table 2) . Overall, these data are consistent with the hypothesis that pathological B cell clones are responsible for acquired C1-INH deficiency.
Ten patients had no apparent hematologic disease at diagnosis or during follow up. Eight of them had anti-C1-INH autoantibodies and two had autoantibodies and a non-hematological malignancy.
According to the data of the Italian cancer registry, the incidence of NHL is 114:100,000. This report confirms that the risk of NHL is markedly increased in patients with AAE. The variety of clinical presentations and response to therapy of NHL suggest that the course of B cell malignancies in these patients has no specific characteristics. The same seems to be true for MGUS, which does not progress to multiple myeloma with increased frequency. Finally, the coexistence in AAE patients of true B cell malignancy, non malignant B cell proliferation and pathogenic autoimmune responses suggest that etiopathogenesis of AAE is dominated by an altered control of B cell proliferation. Thus patients with AAE should be closely monitored for signs of lymphoprolipherative disease.
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